Skip to main content
The NCI Community Hub will be retiring in May 2024. For more information please visit the NCIHub Retirement Page:

Baylor Residual breast cancer

By Creighton C1, Lewis M1, Chang J1, Jonathan Bistline2

1. Baylor College of Medicine 2. Broad Institute



Published on


Residual breast cancers after conventional therapy display mesenchymal as tumor-initiating features.  There are four (4) files included in this study:

  1. Sample Annotation (combined_sample_annotation.txt)
  2. Gene expression data from CD44+/CD24- cells sorted by flow cytometry (GSE7513.gct)
    Human breast tumor samples were sorted using flow cytometry to select for cells that were CD44+ and CD24-. Gene expression profiles of these cells were compared with profiles of the other sorted cells (CD24+ and CD44-/CD24-).  GEO Accession GSE7513.
  3. Gene expression data from cancer mammospheres and bulk tumors (GSE7515.gct)
    Isolated single cell suspensions from primary breast cancers were plated onto non-adherent (polyhema-coated) plastic, counted with a hematocytometer, and 20,000 cells were then seeded into a 6-well ultra-low attachment plate supplemented with 2mL MEGM, with the addition of 2 mL of freshly unfrozen MEGM every 3-4 days. Gene expression profiles were taken of both MS and primary bulk tumors and compared with each other.  GEO Accession: GSE7515
  4. Letrozole (Femara) early response to treatment (GSE10281.gct)
    Biopsies were taken from the same subjects both pretreatment and after 10-14 days Letrozol, 2.5 mg/day, oral.  GEO Accession GSE10281

These datasets have been exported from the Broad Institute's ICBP Data & Analysis Portal.


Creighton C, Lewis M, Chang J

Sponsored by

Baylor College of Medicine, Broad Institute of MIT & Harvard

Cite this work

Researchers should cite this work as follows:

  • Creighton C; Lewis M; Chang J; Jonathan Bistline (2014), "Baylor Residual breast cancer,"

    BibTex | EndNote